| Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults AJ Lucendo, J Molina-Infante, Á Arias, U von Arnim, AJ Bredenoord, ... United European gastroenterology journal 5 (3), 335-358, 2017 | 981 | 2017 |
| The endogenous cannabinoid system protects against colonic inflammation F Massa, G Marsicano, H Hermann, A Cannich, K Monory, BF Cravatt, ... The Journal of clinical investigation 113 (8), 1202-1209, 2004 | 561 | 2004 |
| Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, HJ Woerle, ... Gut 55 (2), 243-251, 2006 | 338 | 2006 |
| Distribution, function and physiological role of melatonin in the lower gut CQ Chen, J Fichna, M Bashashati, YY Li, M Storr World journal of gastroenterology: WJG 17 (34), 3888, 2011 | 289 | 2011 |
| Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by 1H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and … R Schicho, R Shaykhutdinov, J Ngo, A Nazyrova, C Schneider, ... Journal of proteome research 11 (6), 3344-3357, 2012 | 270 | 2012 |
| The pathophysiology of chronic constipation CN Andrews, M Storr Canadian Journal of Gastroenterology and Hepatology 25, 16B-21B, 2011 | 242 | 2011 |
| Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives M Sobczak, M Sałaga, MA Storr, J Fichna Journal of gastroenterology 49, 24-45, 2014 | 223 | 2014 |
| Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease A Wasilewski, M Zielińska, M Storr, J Fichna Inflammatory bowel diseases 21 (7), 1674-1682, 2015 | 215 | 2015 |
| Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity S Klein, B Seidler, A Kettenberger, A Sibaev, M Rohn, R Feil, ... Nature communications 4 (1), 1630, 2013 | 214 | 2013 |
| Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis MA Storr, CM Keenan, H Zhang, KD Patel, A Makriyannis, KA Sharkey Inflammatory bowel diseases 15 (11), 1678-1685, 2009 | 213 | 2009 |
| Eosinophilic colitis: epidemiology, clinical features, and current management AA Alfadda, MA Storr, EA Shaffer Therapeutic advances in gastroenterology 4 (5), 301-309, 2011 | 201 | 2011 |
| Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease M Storr, S Devlin, GG Kaplan, R Panaccione, CN Andrews Inflammatory bowel diseases 20 (3), 472-480, 2014 | 198 | 2014 |
| Treatment of achalasia: botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-up HD Allescher, M Storr, M Seige, R Gonzales-Donoso, R Ott, P Born, ... Endoscopy 33 (12), 1007-1017, 2001 | 195 | 2001 |
| Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors MA Storr, CM Keenan, D Emmerdinger, H Zhang, B Yüce, A Sibaev, ... Journal of molecular medicine 86, 925-936, 2008 | 191 | 2008 |
| Brain-gut interactions in IBS J Fichna, MA Storr Frontiers in pharmacology 3, 127, 2012 | 184 | 2012 |
| The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract F Massa, M Storr, B Lutz Journal of molecular medicine 83, 944-954, 2005 | 179 | 2005 |
| STW 5 (Iberogast®)—a safe and effective standard in the treatment of functional gastrointestinal disorders B Ottillinger, M Storr, P Malfertheiner, HD Allescher Wiener Medizinische Wochenschrift (1946) 163 (3-4), 65, 2013 | 175 | 2013 |
| Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up M Storr, HD Allescher, T Rösch, P Born, N Weigert, M Classen Gastrointestinal endoscopy 54 (6), 754-759, 2001 | 151 | 2001 |
| The endocannabinoid system and gut–brain signalling MA Storr, KA Sharkey Current opinion in pharmacology 7 (6), 575-582, 2007 | 148 | 2007 |
| IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro S Brand, J Dambacher, F Beigel, K Zitzmann, MHJ Heeg, TS Weiss, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 292 (4 …, 2007 | 143 | 2007 |
